theMednetRegister

Endocrinology

Preventive Cardiology   

Questions discussed in this category

How do you counsel patients with metabolic syndrome who decline statin therapy and have low coronary calcium scores regarding their long-term CVD risk?
3 Answers available
For a patient with known CAD and low baseline HDL, would a PCSK9 inhibitor be a better option than a statin, given concerns for paradoxical lowering of HDL levels with statin therapy that we can encounter in the outpatient clinical setting? 
5 Answers available
What is the clinical significance of a paradoxical decrease in HDL cholesterol after starting statin therapy?
2 Answers available
How often do you recommend performing an advanced lipid panel for monitoring of lipid lowering therapy?
4 Answers available
Under what clinical circumstances, if any, would you prescribe fenofibrate along with statin therapy?
2 Answers available
Is there any difference in the cardiovascular risk reduction profile of brand name Vascepa versus generic icosapent ethyl for patients with hypertriglyceridemia?
1 Answer available
How should we approach the recommendation of intermittent fasting for weight loss in patients with pre-existing cardiovascular conditions, given the observed association of increased CV mortality with eating durations of less than 8 hrs?
Chen & Zhong, AHA/ASA Journals 2024
2 Answers available
What other considerations for hyperlipidemia management would you have for a patient with multiple prior PCIs whose LDL remains above goal on high intensity statin, ezetimibe, and evolocumab, assuming the patient is compliant with medications?
3 Answers available
Do you start a statin concurrently with icosapent ethyl for patients with moderate hypertriglyceridemia and high ASCVD risk, or do you prefer to start a statin alone and monitor triglyceride levels?
Moderate hypertriglyceridemia is defined here as a triglyceride level of 150-499 mg/dL.
2 Answers available
Would the diagnostic yield for ABIs or peripheral arterial duplex doppler in a patient with metal rods in both legs be similar or acceptable in comparison to those tests in a patient without metal rods? 
1 Answer available
Would you consider adding niacin to the lipid lowering regimen in statin-intolerant patients who cannot afford PCSK9i or bempedoic acid?
Ferrell et al., PMID 38448791
6 Answers available
Will TRYNGOLZA (olezarsen), recently approved for familial chylomicronemia syndrome, also lower triglycerides due to other genetic causes of hypertriglyceridemia?
2 Answers available
Is moderate-intensity statin plus ezetimibe just as effective as high-intensity statin monotherapy in preventing major cardiovascular events?
4 Answers available
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
Prattichizzo et al., PMID 39468384
1 Answer available
Would you recommend statin initiation in a young adult patient (age < 40) with type 1 diabetes mellitus and LDL cholesterol levels greater than 100 without any cardiovascular risk factors?
1 Answer available
Should we recommend SGLT2i initiation at discharge to all patients hospitalized with acute myocardial infarction?
Butler et al., PMID 38587237
1 Answer available
Does oral semaglutide provide similar cardiovascular risk reduction benefits as injectable semaglutide?
1 Answer available
Do you recommend the use of bempedoic acid (Nexletol) for treatment of hyperlipidemia in patients with elevated baseline uric acid levels?
Should uric acid levels be monitored regularly while on therapy?
1 Answer available
Should low-intensity statins be favored to minimize the risk of diabetes onset while still offering cardiovascular benefit for patients with prediabetes where a statin is indicated?
Cholesterol Treatment Trialists' (CTT) Collaboration
2 Answers available
How do you counsel patients with non-statin associated inflammatory myopathies about statin use?
1 Answer available


Papers discussed in this category

Lancet (London, England), 2023 Mar 06
Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.
Curr Rheumatol Rep, 2020 Aug 26
Lipid-lowering Therapies in Myositis.
The New England journal of medicine, 2024 Apr 06
Empagliflozin after Acute Myocardial Infarction.
The American journal of cardiology, 2004-02-01
Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).
Nature medicine, 2024 Feb 19
A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk.
Journal of clinical lipidology, 2024 Mar 29
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice.
Journal of the American College of Cardiology, 1986-12
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
The New England journal of medicine, 2011-12-15
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
Current opinion in lipidology, 2007 Aug
Niacin in cardiovascular prevention: mechanisms, efficacy, and safety.
The American journal of cardiology, 2005 Jun 01
Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.
Trials, 2018 Mar 05
Improved adherence adjustment in the Coronary Drug Project.
The New England journal of medicine, 2014 Jul 17
Effects of extended-release niacin with laropiprant in high-risk patients.
JAMA, 1975 Jan 27
Clofibrate and niacin in coronary heart disease.
The New England journal of medicine, 2016 Sep 15
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
The New England journal of medicine, 2019-01-03
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
The New England journal of medicine, 2023 Nov 11
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
The New England journal of medicine, 2024 Apr 07
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
The New England journal of medicine, 2022 Apr 21
Calorie Restriction with or without Time-Restricted Eating in Weight Loss.
The lancet. Healthy longevity, 2024 Apr 05
Effects of 3 months of 10-h per-day time-restricted eating and 3 months of follow-up on bodyweight and cardiometabolic health in Danish individuals at high risk of type 2 diabetes: the RESET single-centre, parallel, superiority, open-label, randomised controlled trial.
Diabetes & metabolic syndrome, 2024 Feb 05
Does early time-restricted eating reduce body weight and preserve fat-free mass in adults? A systematic review and meta-analysis of randomized controlled trials.
Journal of clinical lipidology, 2022 Sep 11
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association.
Ophthalmology, 2014-12
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Lancet (London, England), 2007 Nov 07
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.
NEJM evidence, 2024 Jun 21
Effect of Fenofibrate on Progression of Diabetic Retinopathy.

Related Topics in Endocrinology

Copyright © 2025 theMednet
All Rights Reserved.